Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex with Dose-Intense Temozolomide in Recurrent Glioblastoma
NCT01812616Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Sativex + Temozolomide with Placebo + Temozolomide (2 arms). Primary endpoint: Incidence of Adverse Events as a Measure of Patient Safety. Started Sep 2014; status: completed.
02
Drugs
cannabidiol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01812616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812616.